One emerging trend to face the challenges of drug development productivity is the deployment of integrated networks of specialized partners that each focus on their core competence to bring excellence to each development stage. Genexion believes it is well positioned to take part in such integrated networks. By leveraging its specialized core capabilities in clinical development, Genexion is poised to play a pivotal role along the value chain leading to late stage products.

Genexion's partnering strategy is to pursue collaborations in its target therapeutic areas including co-development and in-licensing agreements. In such partnerships, Genexion designs and executes fast-track development programs to maximize the potential of promising products and substantially enhance their market value.

Genexion is a particularly well suited partner for small biotechnology companies, that are often seeking optimum clinical development capabilities. Genexion brings them the technical, clinical and financial assets required to maximize market value of their products.

Genexion's partnering strategy also includes collaborations with outstanding service and technology providers. With these alliances, Genexion continues to complement its development platform with innovative tools and exclusive technology assets.